CryoCor has decided to lay off 20 of 58 employees as it focuses on gaining approval for a new therapy for irregular heartbeat. Earlier this month the FDA told CryoCor that its trial data did not support an approval for the treatment, which involves freezing tissue that physicians believe causes atrial fibrillation. The therapy was approved in Europe in 2002 and CryoCor executives appear hopeful that more data may change the FDA's mind.
- read this article from the San Diego Union-Tribune